Pegylated liposomal doxorubicin in the treatment of primary cutaneous T-cell lymphomas

Stefano Pulini, Serena Rupoli, Gaia Goteri, Nicola Pimpinelli, Renato Alterini, Angela Tassetti, Anna Rita Scortechini, Massimo Offidani, Simonetta Mulattieri, Andrea Stronati, Giuliano Brandozzi, Alfredo Giacchetti, Giorgio Mozzicafreddo, Giuseppe Ricotti, Giorgio Filosa, Alberta Bettacchi, Marco Simonacci, Nicolino Novelli, Pietro Leoni

Research output: Contribution to journalArticlepeer-review

Abstract

Pegylated liposomal doxorubicin (Peg-Doxo) is a promising drug for advanced/recalcitrant primary cutaneous T-cell lymphomas (CTCLs). This prospective phase II trial enrolled 19 patients. We observed overall and complete response rates of 84.2% and 42.1% (with no significant differences between stage I-IIA and IIB-IV patients), and 11% grade III/IV toxicity. After a maximum 46 month-follow-up, median overall (OS), event-free (EFS) and progression-free (PFS) survival were 34, 18 and 19 months. OS, EFS and PFS rates at 46 months were 44%, 30% and 37% respectively. Peg-Doxo seems to be an active and safe principle that should be used in plurirelapsed, early stage-MF and in combination with other chemotherapeutic agents in advanced and aggressive CTCLs.

Original languageEnglish
Pages (from-to)686-689
Number of pages4
JournalHaematologica
Volume92
Issue number5
DOIs
Publication statusPublished - May 2007

Keywords

  • Mycosis fungoides
  • Pegylated liposomal doxorubicin
  • Primary cutaneous T-cell lymphomas
  • Sézary syndrome

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Pegylated liposomal doxorubicin in the treatment of primary cutaneous T-cell lymphomas'. Together they form a unique fingerprint.

Cite this